Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Brentuximab | |
| Synonyms |
Monoclonal Antibody SGN-30 Anti-CD30 Monoclonal Antibody BRENTUXIMAB Brentuximab CAC-10 CAC10 SGN-30 SGN30 |
|
| Definitions |
A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2007 |
|
| ALT_DEFINITION |
A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.
|
|
| CAS_Registry |
775303-41-8
|
|
| code |
C2007
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC
|
|
| DEFINITION |
A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.
|
|
| Display_Name |
Brentuximab
|
|
| FDA_UNII_Code |
C67ORA155P
|
|
| FULL_SYN |
Monoclonal Antibody SGN-30 Anti-CD30 Monoclonal Antibody BRENTUXIMAB Brentuximab CAC-10 CAC10 SGN-30 SGN30
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Brentuximab
|
|
| Legacy Concept Name |
SGN-30
|
|
| Maps_To |
Brentuximab
|
|
| NCI_Drug_Dictionary_ID |
357600
|
|
| NSC Number |
731636
|
|
| PDQ_Closed_Trial_Search_ID |
357600
|
|
| PDQ_Open_Trial_Search_ID |
357600
|
|
| Preferred_Name |
Brentuximab
|
|
| prefixIRI |
Thesaurus:C2007
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor
|
|
| UMLS_CUI |
C1328236
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
| Mapping To | Ontology | Source |
|---|---|---|
| http://purl.obolibrary.org/obo/NCIT_C2007 | BERO | LOOM |
| http://purl.bioontology.org/ontology/VANDF/4031046 | VANDF | LOOM |
| http://purl.bioontology.org/ontology/NDFRT/N0000183554 | NDFRT | LOOM |